Clinical Trial

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.
Protocol Amendment History 1 change
notable Trial sites expanded: 69 -> 75 locations 2026-06-04
Trial Details
NCT Number NCT07047365
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions HER2-positive Advanced Breast Cancer
Enrollment 416 participants
Start Date 2025-07-25
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-03